After decades of failed drug trials, two new drugs have emerged in slowing memory loss associated with Alzheimer's disease: Leqembi and Donanemab. In Episode #015 I deep dive into novel Alzheimer's therapies to discuss their effectiveness, safety, and how to find out if you're at risk.
Chapters:
(0:00) Introduction
(2:00) Who's most at risk of Alzheimer's Disease?
(5:52) The Amyloid Hypothesis
(7:14) Leqembi approved by FDA
(9:16) Donanenmab may be next
(12:10) Alzheimer's drugs, brain bleeding, and death
(16:01) How do you know if you have Alzheimer's?
(21:20) Dementia and CTE
(22:49) Do taking smart drugs make us more productive? Is it worth the risk?
(27:00) The Connect - viewers' comments from previous episodes
Show Notes:
Alzheimer’s drug being tested Leqembi or Lecanemab
Donanemab:
Systematic failure of Alzheimer’s drug trials:
Are these drugs safe?
Symptoms of Alzheimer’s:
Mini Mental State Examination (MMSE)
https://cgatoolkit.ca/Uploads/ContentDocuments/MMSE.pdf
CTE in female athlete:
Smart drugs make you dumb:
Thanks for reading BioLab Collective with Jack Wang! Subscribe for free to receive new posts and support my work.
